alanine has been researched along with lisinopril in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbate, M; Benigni, A; Cassis, P; Cerullo, D; Corna, D; Locatelli, M; Remuzzi, G; Rottoli, D; Villa, S; Zoja, C | 1 |
| Li, B; Wang, H; Wu, J | 1 |
2 other study(ies) available for alanine and lisinopril
| Article | Year |
|---|---|
Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy.
Topics: Alanine; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Half-Life; Humans; Kidney Glomerulus; Lisinopril; Male; Mice; Mice, Transgenic; Microscopy, Electron, Transmission; Peptide Fragments; Peptides, Cyclic; Proteinuria; Sulfides | 2019 |
Structure-aided ACEI-capped remdesivir-loaded novel PLGA nanoparticles: toward a computational simulation design for anti-SARS-CoV-2 therapy.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; COVID-19 Drug Treatment; Drug Carriers; Drug Synergism; Humans; Lisinopril; Molecular Docking Simulation; Molecular Dynamics Simulation; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Protein Binding; SARS-CoV-2 | 2020 |